Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

This study is testing whether adding a drug that blocks tumour blood vessel growth (a VEGF inhibitor) can allow doctors to safely deliver higher doses of radiation to glioblastoma — the most aggressive form of brain cancer — while reducing damage to surrounding healthy brain tissue. **You may be eligible if...** - You have been diagnosed with IDH wild-type, MGMT unmethylated glioblastoma (a specific type of aggressive brain tumour) - You are between 18 and 70 years old - Your overall health is good enough (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your glioblastoma has different genetic features (IDH-mutant or MGMT-methylated) - You have significant kidney problems or high levels of protein in your urine - You are not able to use adequate contraception - You have certain blood-clotting disorders or uncontrolled high blood pressure Talk to your doctor to see if this trial is right for you.